Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

被引:136
|
作者
Emuss, V
Garnett, M
Mason, C
Marais, R
机构
[1] Inst Canc Res, Signal Transduct Team, Canc Res UK, Ctr Cell & Mol Biol, London SW3 6JB, England
[2] Wellcome Trust Sanger Inst, Hinxton, England
基金
英国惠康基金;
关键词
D O I
10.1158/0008-5472.CAN-05-1683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The protein kinase B-RAF is mutated in similar to 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.
引用
收藏
页码:9719 / 9726
页数:8
相关论文
共 50 条
  • [41] Determining the role of non-mutated C-Raf kinase in metastatic disease
    Ta, Lisa H.
    Carr-Ascher, Janai R.
    Deng, Weixian
    Tsai, Brandon L.
    Tran, Wendy
    Gun, Donny
    Cheng, Donghui
    Sha, Jihui
    Hwang, Yeonjoo
    Phillips, John W.
    Obusan, Matthew B.
    Bangayan, Nathanael J.
    Noguchi, Miyako
    Mao, Zhiyuan
    Chen, Chia-Chun
    Wang, Liang
    Varuzhanyan, Grigor
    Gordon, John D.
    Wohlschlegel, James W.
    Witte, Owen N.
    CANCER RESEARCH, 2022, 82 (12)
  • [42] PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
    Xiaojuan Wang
    Fan Wu
    Han Wang
    Xiaoyuan Duan
    Rong Huang
    Amannisa Tuersuntuoheti
    Luying Su
    Shida Yan
    Yuechao Zhao
    Yan Lu
    Kai Li
    Jinjie Yao
    Zhiwen Luo
    Lei Guo
    Jianmei Liu
    Xiao Chen
    Yalan Lu
    Hanjie Hu
    Xingchen Li
    Mandula Bao
    Xinyu Bi
    Boyu Du
    Shiying Miao
    Jianqiang Cai
    Linfang Wang
    Haitao Zhou
    Jianming Ying
    Wei Song
    Hong Zhao
    Journal of Experimental & Clinical Cancer Research, 39
  • [43] PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
    Wang, Xiaojuan
    Wu, Fan
    Wang, Han
    Duan, Xiaoyuan
    Huang, Rong
    Tuersuntuoheti, Amannisa
    Su, Luying
    Yan, Shida
    Zhao, Yuechao
    Lu, Yan
    Li, Kai
    Yao, Jinjie
    Luo, Zhiwen
    Guo, Lei
    Liu, Jianmei
    Chen, Xiao
    Lu, Yalan
    Hu, Hanjie
    Li, Xingchen
    Bao, Mandula
    Bi, Xinyu
    Du, Boyu
    Miao, Shiying
    Cai, Jiandiang
    Wang, Linfang
    Zhou, Haitao
    Ying, Jianming
    Song, Wei
    Zhao, Hong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [44] Functional cross-talk between cAMP and ERK1/2 pathway promotes proliferation of somatotropinomas in a B-Raf and C-Raf dependent manner
    Jiao, Wei
    Huang, Yimin
    Sun, Wei
    Wang, Junwen
    Lei, Ting
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (04): : 4137 - 4149
  • [45] C-raf antisense treatment enhances paclitaxel cytotoxicity in human tumor cells
    RasouliNia, A
    Liu, D
    Perdue, S
    Britten, RA
    CANCER GENE THERAPY, 1997, 4 (06) : P17 - P17
  • [46] Associations of B- and C-raf with cholesterol, phosphatidylserine, and lipid second messengers - Preferential binding of Raf to artificial lipid rafts
    Hekman, M
    Hamm, H
    Villar, AV
    Bader, B
    Kuhlmann, J
    Nickel, J
    Rapp, UR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) : 24090 - 24102
  • [47] Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity
    Zaraei, Seyed-Omar
    Al-Ach, Nour N.
    Anbar, Hanan S.
    El-Gamal, Randa
    Tarazi, Hamadeh
    Tokatly, Rimas T.
    Kalla, Rawan R.
    Munther, Mouna A.
    Wahba, Marwa M.
    Alshihabi, Aya M.
    Shehata, Mahmoud K.
    Sbenati, Rawan M.
    Shahin, Afnan I.
    El-Awady, Raafat
    Al-Tel, Taleb H.
    El-Gamal, Mohammed I.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238
  • [48] High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
    Al Shahrani, Mesfer
    Abohassan, Mohammad
    Y. Alshahrani, Mohammad
    Hakami, Abdulrahim R.
    Rajagopalan, Prasanna
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2021, 35 (12) : 1165 - 1176
  • [49] C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E
    Karreth, Florian A.
    DeNicola, Gina M.
    Winter, Stephen P.
    Tuveson, David A.
    MOLECULAR CELL, 2009, 36 (03) : 477 - 486
  • [50] High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
    Mesfer Al Shahrani
    Mohammad Abohassan
    Mohammad Y. Alshahrani
    Abdulrahim R. Hakami
    Prasanna Rajagopalan
    Journal of Computer-Aided Molecular Design, 2021, 35 : 1165 - 1176